Aroa Biosurgery Future Growth
Future criteria checks 5/6
Aroa Biosurgery is forecast to grow earnings and revenue by 114.9% and 20.6% per annum respectively. EPS is expected to grow by 114.5% per annum. Return on equity is forecast to be 6.1% in 3 years.
Key information
114.9%
Earnings growth rate
114.5%
EPS growth rate
| Biotechs earnings growth | 16.0% |
| Revenue growth rate | 20.6% |
| Future return on equity | 6.1% |
| Analyst coverage | Low |
| Last updated | 30 Apr 2024 |
Recent future growth updates
Recent updates
Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation
Mar 25
Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge
Jan 30Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors
Nov 14Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts
Nov 02Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price
Oct 25We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth
May 13Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results
May 26An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued
Mar 22Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?
Feb 24Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)
Feb 24Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 44% Above Its Share Price
Dec 16
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 134 | N/A | N/A | N/A | 1 |
| 3/31/2026 | 111 | 14 | 11 | 7 | 5 |
| 3/31/2025 | 87 | 2 | -5 | 1 | 5 |
| 3/31/2024 | 68 | -7 | -13 | -10 | 5 |
| 9/30/2023 | 66 | -8 | -15 | -6 | N/A |
| 6/30/2023 | 65 | -4 | -13 | -5 | N/A |
| 3/31/2023 | 63 | 0 | -11 | -4 | N/A |
| 12/31/2022 | 57 | -1 | -13 | -7 | N/A |
| 9/30/2022 | 51 | -2 | -15 | -10 | N/A |
| 6/30/2022 | 45 | -5 | -16 | -11 | N/A |
| 3/31/2022 | 40 | -8 | -16 | -12 | N/A |
| 12/31/2021 | 35 | -10 | -14 | -10 | N/A |
| 9/30/2021 | 31 | -11 | -11 | -8 | N/A |
| 6/30/2021 | 27 | -15 | -9 | -6 | N/A |
| 3/31/2021 | 22 | -19 | -7 | -5 | N/A |
| 12/31/2020 | 22 | -19 | -6 | -5 | N/A |
| 9/30/2020 | 21 | -19 | -6 | -4 | N/A |
| 6/30/2020 | 23 | -12 | -3 | -1 | N/A |
| 3/31/2020 | 25 | -6 | 0 | 2 | N/A |
| 3/31/2019 | 24 | 1 | -2 | 0 | N/A |
| 3/31/2018 | 11 | -1 | -5 | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: ARX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ARX is expected to become profitable in the next 3 years.
Revenue vs Market: ARX's revenue (20.6% per year) is forecast to grow faster than the Australian market (5% per year).
High Growth Revenue: ARX's revenue (20.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ARX's Return on Equity is forecast to be low in 3 years time (6.1%).